Sarcoma
Welcome,         Profile    Billing    Logout  
 515 Companies   302 Products   302 Products   167 Mechanisms of Action   1404 Trials   125634 News 


«12...14911492149314941495149614971498149915001501...15771578»
  • ||||||||||  metformin / Generic mfg.
    Journal:  Metabolic modulation of Ewing sarcoma cells inhibits tumor growth and stem cell properties. (Pubmed Central) -  Nov 5, 2017   
    Thus, metabolic inhibitors of glycolysis such as 2-deoxy-D-glucose (2DG) and of the mitochondrial respiratory pathway, such as metformin, were evaluated as potential therapeutic agents against a panel of EWS cell lines in vitro...Furthermore, we demonstrate that the use of metabolic modulators can target putative EWS stem cells, both in vitro and in vivo, and potentially overcome chemotherapeutic resistance in EWS. Based on these data, clinical strategies using drugs targeting tumor cell metabolism present a viable therapeutic modality against EWS.
  • ||||||||||  Journal:  Targeting isocitrate dehydrogenase (IDH) in cancer. (Pubmed Central) -  Nov 5, 2017   
    Preliminary results from phase I clinical trials with IDH inhibitors in patients with advanced hematologic malignancies have demonstrated an objective response rate ranging from 31% to 40% with durable responses (>1 year) observed. Furthermore, the IDH inhibitors have demonstrated early signals of activity in solid tumors with IDH mutations, including cholangiocarcinomas and low grade gliomas.
  • ||||||||||  Journal:  Intracardiac Low-grade Sarcoma Following Treatment for Ewing Sarcoma. (Pubmed Central) -  Nov 5, 2017   
    Despite the near-synchronous presentation of 2 unrelated sarcomas, extensive genomic analyses did not reveal any unifying somatic or germline mutations nor any apparent cancer predisposition. This case also highlights the potential role of utilizing plasma cell-free DNA for diagnosing tumors in locations where biopsy confers high morbidity.
  • ||||||||||  Biomarker, Review, Journal:  Autophagy as a potential target for sarcoma treatment. (Pubmed Central) -  Nov 5, 2017   
    Additionally, some co-regulators of autophagy have also been investigated as promising biomarkers for the diagnosis and prognosis of sarcoma. In this review, we summarize contemporary advances in the role of autophagy in sarcoma and discuss the potential of autophagy as a new target for sarcoma treatment.
  • ||||||||||  Xalkori (crizotinib) / Pfizer
    Journal:  An activating KIT mutation induces crizotinib resistance in ROS1 positive lung cancer. (Pubmed Central) -  Nov 3, 2017   
    Activation of KIT by a gain-of-function somatic mutation is a novel mechanism of resistance to crizotinib in ROS1-rearranged NSCLC. This bypass signaling pathway serves as a ROS1-independent mechanism of resistance, similarly to previously identified epidermal growth factor receptor or Kirsten rat sarcoma viral oncogene homolog/neuroblastoma RAS viral oncogene homolog signaling pathways, and can potentially be targeted by KIT inhibitors.
  • ||||||||||  Journal:  The Width of the Surgical Margin Does Not Influence Outcomes in Extremity and Truncal Soft Tissue Sarcoma Treated With Radiotherapy. (Pubmed Central) -  Nov 3, 2017   
    In patients undergoing radiation therapy and limb-sparing surgery for soft tissue sarcoma, the quantitative width of the negative margin does not influence outcome, and so attempts at wide margins of resection appear to be unnecessary, especially when such attempts compromise the functional outcome. Importantly, the conclusions drawn from this study must not be applied to those patients undergoing surgery alone as the local treatment of their soft tissue sarcoma, in which case wider margins of resection may be necessary.
  • ||||||||||  Biomarker, Journal:  Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy. (Pubmed Central) -  Nov 2, 2017   
    This is a case report of an Ewing sarcoma patient with metastatic disease recurrence <2 years after standard chemotherapy/radiation who achieved a durable and sustained complete response after 2 series of treatments with Vigil (GMCSF/bi-shRNA furin DNA autologous tumor immunotherapy) serially manufactured from first and second recurrences with ELISPOT assay correlation. Results support justification of further testing of Vigil with ELISPOT assay as a biomarker to assess level of immune response and correlation with disease control.
  • ||||||||||  Journal:  Clinical case series of pediatric hepatic angiosarcoma. (Pubmed Central) -  Nov 2, 2017   
    Seven were initially diagnosed with an infantile hepatic hemangioendothelioma (IHHE) or hemangioma and the eighth with a "vascular tumor." Two patients, who received liver transplant, survived. We suggest hepatic hemangiomas can rarely transform into angiosarcomas and a subset of IHHEs (Type II) are actually a low-grade form of angiosarcoma rather than a benign lesion.
  • ||||||||||  Journal:  Unusual abdominal metastases in osteosarcoma. (Pubmed Central) -  Nov 1, 2017   
    Awareness of and surveillance for unusual patterns of metastasis may allow for earlier detection, intervention, and palliative care decision-making, which may affect survival and quality of life. This report underlines the need for prospective studies evaluating surveillance guidelines for patients after medical and surgical management of osteosarcoma, especially in cases complicated by pulmonary metastases.
  • ||||||||||  Journal:  Morbidity and mortality after treatment of Ewing sarcoma: A single-institution experience. (Pubmed Central) -  Oct 28, 2017   
    Excellent local control can be achieved with a coordinated strategy of preoperative (±intraoperative) XRT combined with aggressive en bloc surgical resection of RPS, but systemic failure remains a problem for higher-grade tumors. Patients with ES are at high risk for relapse/progression and second cancers.
  • ||||||||||  Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, Halaven (eribulin mesylate) / Eisai
    Review, Journal:  Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma? (Pubmed Central) -  Oct 28, 2017   
    Also, to be further investigated is the use of trabectedin in sarcoma subtypes which were excluded from the phase III study, but in which activity has been documented in earlier trials and subsequent reports. Combinations of trabectedin with other agents, particularly doxorubicin, have been explored, but the data to date do not support the routine use of these regimens.
  • ||||||||||  PX-478 / Seagen
    Journal:  Hypoxia-inducible factor-1 alpha as a therapeutic target for primary effusion lymphoma. (Pubmed Central) -  Oct 28, 2017   
    Consistent with these findings, we observed a significant inhibition of growth of PEL in normoxia upon HIF-1α suppression achieved by either HIF-1α knockdown or treatment with PX-478, a small molecule inhibitor of HIF-1α. These results offer further evidence that HIF-1α plays a critical role in the pathogenesis of PEL, and that inhibition of HIF-1α can be a potential therapeutic strategy in this disease.
  • ||||||||||  Enrollment change:  Genomic Structural Variation in Cancer Susceptibility (clinicaltrials.gov) -  Oct 26, 2017   
    P=N/A,  N=1850, Enrolling by invitation, 
    Recruiting --> Active, not recruiting | N=24 --> 17 | Trial primary completion date: Jul 2019 --> Mar 2017 N=1250 --> 1850
  • ||||||||||  Zolinza (vorinostat) / Merck (MSD)
    Trial primary completion date, Combination therapy:  Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas (clinicaltrials.gov) -  Oct 25, 2017   
    P1,  N=83, Active, not recruiting, 
    Trial primary completion date: Jul 2007 --> Oct 2017 Trial primary completion date: Oct 2007 --> Oct 2011
  • ||||||||||  adavosertib (AZD1775) / AstraZeneca
    Trial primary completion date, Combination therapy:  Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) -  Oct 24, 2017   
    P1/2,  N=128, Recruiting, 
    Unlike t(1;10), BRAF rearrangements were only found in MIFS but not in 6 hemosiderotic fibrolipomatous tumor (HFLT) lacking TGFBR3-MGEA5 fusions (including 2 pure HFLT, 2 hybrid HFLT-MIFS, and 2 associated with pleomorphic hyalinizing angiectatic tumors). Trial primary completion date: Oct 2017 --> Apr 2021
  • ||||||||||  ONCT-216 / Oncternal Therap
    Trial primary completion date:  TK216-01: TK216 in Patients With Relapsed or Refractory Ewing Sarcoma (clinicaltrials.gov) -  Oct 24, 2017   
    P1,  N=45, Recruiting, 
    Trial primary completion date: Oct 2017 --> Apr 2021 Trial primary completion date: Dec 2017 --> Sep 2018
  • ||||||||||  adegramotide/nelatimotide (DSP-7888) / Sumitomo Pharma
    Enrollment change, Trial primary completion date, Metastases:  A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (clinicaltrials.gov) -  Oct 24, 2017   
    P1,  N=96, Recruiting, 
    Trial primary completion date: Sep 2017 --> Sep 2018 N=76 --> 96 | Trial primary completion date: Nov 2017 --> Aug 2018
  • ||||||||||  Lartruvo (olaratumab) / Eli Lilly
    Combination therapy, Monotherapy:  A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma (clinicaltrials.gov) -  Oct 24, 2017   
    P1b,  N=40, Recruiting, 
    N=76 --> 96 | Trial primary completion date: Nov 2017 --> Aug 2018 Trial primary completion date: Apr 2018 --> Jul 2018
  • ||||||||||  Biomarker, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker:  I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) -  Oct 20, 2017   
    P2,  N=1920, Recruiting, 
    These data show the relative preservation of truncal chromosomal abnormalities between conventional and sarcomatoid morphologic as well as matched metastatic settings. Trial primary completion date: Dec 2018 --> Dec 2020